Otsuka Pharmaceutical Factory completes acquisition of additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara; "OPF") today completed the acquisition of the outstanding shares held by Mitsui & Co., Ltd.* in Otsuka's Indian joint venture subsidiary, Otsuka Pharmaceutical India Private Limited ("OPI"). Accordingly, OPF now holds 100% of the outstanding equity shares of OPI, making OPI a wholly owned subsidiary of OPF.

OPI is an IV business company in which OPF acquired equity in 2013, in order to enter the IV industry in the promising Indian pharmaceutical market. The company now has presence in over 50 countries and regions outside India as an exporter, as well as business expansion in India. By making OPI a wholly owned subsidiary of the OPF, OPF will maximize the utilization of the technology of basic IV solution and nutrition solution that it has cultivated in Japan, and will strengthen and develop its IV business in India, a country in which significant economic growth and increasingly sophisticated healthcare system are expected.

Under its management vision of "The Best Partner in Clinical Nutrition," OPF will further contribute to maintaining and improving the health of the people of India.

Based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated to contributing to the health of people around the world.

*The agreement for the acquisition of the Mitsui shares was announced on March 20, 2018, "Otsuka Pharmaceutical Factory enters into an agreement to acquire additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited, making it a wholly owned subsidiary."